Our findings indicate that therapies targeting ferroptosis in patients carrying the PNPLA3-I148M variant could affect the development of MASLD and ESLD and highlight the utility of iPSC-based models for the study of genetic contributions to hepatic disorders. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.